It's not that the lab folks at tiny CellPro, Inc. are uninterested in saving lives. It's just that like most biotech researchers, they prefer to toil far away from the gritty reality of illness and human suffering. So when the CEO of their Bothell, Wash., company announced a year ago that he had developed a deadly lymphatic cancer and that his slim chance for survival might rest on their lab results, it was more than they'd bargained for. They already knew their company was fighting for survival, locked in a legal battle over patents with a competitor. Now they were also...
To continue reading:
or
Log-In
